New VP of Development and Analytical Services at Catalent

Sally Langa joins the US drug delivery technology specialist

Catalent Pharma Solutions has a new Vice President of Development and Analytical Services.

Sally Langa has joined the drug delivery technology firm from Halo Pharma where she was Vice President, Sales and Marketing.

Langa's career within the pharmaceutical services industry spans almost 30 years and she has held a number of senior positions at Patheon.

In her new role, Langa will be responsible for growing Catalent’s early phase development business for small molecule compounds, including analytical services, formulation development, and micronisation.

Catalent’s Development and Analytical services, located at sites throughout the US and Europe, offer global solutions with specialist handling capabilities for controlled substances, highly potent, cytotoxic, and temperature critical compounds, to handle the most challenging molecules.

You may also like

Manufacturing

Catalent expands integrated development, manufacturing and supply for modalities

Originally launched in 2019 for early-phase protein therapy development, OneBio Suite offers customers an integrated service
Distribution

Catalent enters commercial supply agreement

Since 2017, Harm Reduction Therapeutics has been working on a low-cost, OTC naloxone product to act as a critical tool to help stem the loss of life
Manufacturing

Catalent expands platform process for viral vectors

Processes can now benefit through increased consistency and efficiency, potentially reducing the time
Manufacturing

Catalent completes $2.2 million expansion to clinical supply facility

The site in Singapore serves the Asia-Pacific region with a wide range of clinical supply services
Drug Delivery

Catalent opens commercial-scale plasmid DNA facility in Belgium

The state-of-the-art facility contains over 12,000 sqft of development and manufacturing space across multiple cleanrooms
Drug Delivery

Catalent to provide supply chain oversight with Case Management Service

It is set to coordinate the scheduling of material collection, the manufacturing slot for the therapy, arrange shipments and continuously manage its status
Research & Development

Developing optimised formulations with minimal drug substance

Advances in in silico and experimental techniques mean that APIs and prototype formulations can be thoroughly characterised using multiple material-sparing assays, allowing the most promising formulation candidates to move on to in vivo studies, reports Lisa Caralli, Science and Technology Director, Pharmaceutics, Catalent
Subscribe now